Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial

CONCLUSIONS: In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs [Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.PMID:38601287 | PMC:PMC11002487 | DOI:10.21037/gs-24-38

Source: Hand Surgery - April 11, 2024 Category: Surgery Authors: Guolin Ye Peixian Chen Xiangwei Liu Tiancheng He Xavier Pivot Ruilin Pan Dan Zhou Lewei Zhu Kun Zhang Wei Li Shuqing Yang Jiawei Lin Gengxi Cai Huiqi Huang Source Type: research